加载中
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
收盘时
US$10.38
−US$0.31 · -2.90%
盘后
US$10.38
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
日内区间
当前US$10.38
52周区间
当前US$10.38
盘中时间采用ET。市场数据可能有所延迟。
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
日内区间
当前US$10.38
52周区间
当前US$10.38
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 8139.1万 USD | 3327.9万 USD | 1401.7万 USD | 1592万 USD | 3770.1万 USD |
| 销货成本 | 484.3万 USD | 2379.1万 USD | — | — | — |
| 毛利 | 7654.8万 USD | 948.8万 USD | 1401.7万 USD | 1592万 USD | 3770.1万 USD |
| 研究与开发 | 1.3亿 USD | 1.19亿 USD | 1.04亿 USD | 8572.5万 USD | 6669.4万 USD |
| 销售、一般及管理费用 | 5289.7万 USD | 5421.6万 USD | 4729.3万 USD | 4655万 USD | 4376.5万 USD |
| 营业费用 | 1.83亿 USD | 1.74亿 USD | 1.51亿 USD | 1.32亿 USD | 1.1亿 USD |
| 利息收入 | 181.8万 USD | 414.5万 USD | 227.2万 USD | 77.7万 USD | 21.2万 USD |
| 利息支出 | 1219.7万 USD | 1327.2万 USD | 1324.5万 USD | 494.6万 USD | 28.8万 USD |
| 折旧和摊销 | 1254.2万 USD | 1282.8万 USD | 1372.4万 USD | 860.3万 USD | 787.3万 USD |
| 营业利润 | −1.06亿 USD | −1.64亿 USD | −1.37亿 USD | −1.16亿 USD | −7275.8万 USD |
| 净利润 | −1.14亿 USD | −1.48亿 USD | −8402.7万 USD | −1.3亿 USD | −7956.1万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$21.00
上涨空间 102.31%报告持有此股票敞口的交易所交易基金。
iShares Russell 2000 ETFIWM1664.13万0.02%787.4亿 USD0.19%US$277.9-0.37%
First Trust Small Cap Growth AlphaDEX FundFYC664.94万0.49%13.49亿 USD0.70%US$114.85-0.44%
iShares Biotechnology ETFIBB604.42万0.06%108.2亿 USD0.44%US$204.26-1.08%
Vanguard Russell 2000 ETFVTWO477.41万0.03%180亿 USD0.06%US$112.27-0.35%
iShares Russell 2000 Growth ETFIWO464.37万0.03%139.17亿 USD0.24%US$353.71-0.86%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP274.52万0.11%26.34亿 USD0.20%US$65.26-1.64%
First Trust Small Cap Core AlphaDEX FundFYX244.81万0.18%13.4亿 USD0.58%US$135.5+0.09%
Janus Henderson Small Cap Growth Alpha ETFJSML244.19万0.68%3.61亿 USD0.30%US$86.7888-0.79%iShares Russell 2000 ETFIWMFirst Trust Small Cap Growth AlphaDEX FundFYCiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOState Street SPDR S&P Kensho New Economies Composite ETFKOMPFirst Trust Small Cap Core AlphaDEX FundFYXJanus Henderson Small Cap Growth Alpha ETFJSMLAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
